Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

Starting Medication for MTLE-HS

At a Glance

For MTLE-HS, treatment usually starts with one suitable antiseizure medicine, increased carefully to an effective dose and continued long enough to judge response. Seizures after two properly tried medicines warrant referral to a specialized epilepsy center.

Finding the right medication for Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis (MTLE-HS) is the first major step in your treatment journey. While the goal is complete seizure freedom, the process involves balancing effective seizure control with your personal quality of life [1][2].

Selecting Your First Medication

Doctors treat MTLE-HS as a form of focal epilepsy. Because research hasn’t shown one single “winner” that works for everyone, your doctor will choose a medication based on your health history, other medicines you take, and your lifestyle [3][4]. Reproductive counseling is essential: if you plan to become pregnant, or use hormonal birth control, you must discuss this with your clinician, as medications carry different fetal risks and enzyme-inducing interactions.

The most common choices include:

  • Lamotrigine: Often favored for its mild side-effect profile and positive impact on mood [5][2]. It must be started at a very low dose and increased slowly. Urgent Warning: If you develop a new skin rash—especially accompanied by a fever, facial swelling, blisters, or sores—seek urgent medical advice, as it can rarely be life-threatening [6].
  • Levetiracetam: Popular because it works quickly and has very few drug-to-drug interactions [7][8]. Urgent Warning: It can sometimes cause severe behavioral changes like aggression, depression, or suicidal thoughts. Contact a doctor urgently if these occur [5][9].
  • Carbamazepine: A long-standing, effective option for focal seizures [4]. It can, however, interact with many other medications (including birth control, lowering its effectiveness) and requires careful monitoring of your blood levels, liver function, and sodium levels [10][11].

Other options your doctor might discuss include Lacosamide, Zonisamide, or Oxcarbazepine [3][12]. Never abruptly stop taking your antiseizure medication, as this can cause dangerous, prolonged seizures.

What is an ‘Adequate Trial’?

You haven’t “failed” a medication just because you have one seizure after starting it. A true test of a medication, called an adequate trial, requires two things [13][14]:

  1. The Right Dose: You must reach a “therapeutic” or effective dose level. If you stop the drug because of severe side effects before reaching this dose, it is a failure of tolerability, not necessarily of the drug’s seizure-stopping power [15][16].
  2. The Right Time: You generally need to stay on that target dose for enough time to see if your seizure pattern changes.

The Trap of ‘Pseudoresistance’

Sometimes, it looks like medications aren’t working when the real issue is something else. This is called pseudoresistance [16]. Common causes include:

  • Missing Doses: Missing a dose can drop the level of medicine in your brain. Do not improvise if you miss a dose; ask your pharmacist or prescriber for the exact plan for your specific medication [17][14].
  • Wrong Diagnosis: If your events are actually psychogenic nonepileptic seizures, syncope, or a different type of epilepsy, standard focal-seizure meds may not help [16][18].
  • Interactions: Taking certain supplements, herbal remedies, or new prescriptions can interact with your epilepsy medication and change its levels in your body [10][19].

Setting Realistic Expectations

About half of people with new-onset focal epilepsy become seizure-free with their very first medication [1]. If the first one doesn’t work or causes too many side effects, your doctor will likely try a second one, either alone or in combination with the first [20][1].

If your seizures continue after you have tried two different appropriately chosen and adequately dosed medications, your condition is considered drug-resistant [20][16]. At this point, international guidelines recommend a referral to a specialized epilepsy center to discuss other highly effective options [21][16].

Common questions in this guide

Which medication is usually started first for MTLE-HS?
There is no single first medication that works best for everyone with MTLE-HS. Doctors commonly consider lamotrigine, levetiracetam, or carbamazepine for focal seizures, while also weighing your health history, other medicines, lifestyle, pregnancy plans, and birth control.
What makes an antiseizure medication trial adequate?
An adequate trial means reaching the medication’s therapeutic or effective dose and staying at that dose long enough to see whether seizure patterns change. If severe side effects force you to stop before reaching the target dose, that suggests the medication was not tolerated rather than proving it could not control seizures.
How long should I wait before deciding a medication is not working?
Your clinician generally needs you to reach the target dose and remain on it long enough to judge the response; the timing varies by medication and person. One seizure after starting treatment does not automatically mean the medication has failed.
What should I do if I miss a dose of my MTLE-HS medication?
Do not improvise or change the schedule on your own, because instructions vary by medication. Ask your pharmacist or prescriber for the exact plan for the missed dose, and use a pillbox or phone reminder to help prevent future missed doses.
Which medication side effects need urgent attention?
A new rash while taking lamotrigine—especially with fever, facial swelling, blisters, or sores—needs urgent medical advice. Severe behavioral changes such as aggression, depression, or suicidal thoughts while taking levetiracetam also require urgent contact with a doctor.
How can I tell whether my epilepsy is drug-resistant?
MTLE-HS is considered drug-resistant when seizures continue after two different, appropriately chosen medicines have each been tried at an adequate dose for enough time. At that point, guidelines recommend referral to a specialized epilepsy center to discuss further options.
Can MTLE-HS medication affect pregnancy or birth control?
Yes. Different antiseizure medications carry different fetal risks, and some medicines, including carbamazepine, can reduce the effectiveness of hormonal birth control. Discuss pregnancy plans and contraception with your clinician before starting or changing treatment.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Mesial temporal lobe epilepsy with hippocampal sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the medication you are prescribing today considered first-line for focal epilepsy, and why did you choose it specifically for me?
  2. 2.What is the target 'therapeutic dose' for this medication, and how many weeks will it take to safely reach it?
  3. 3.What specific side effects—like skin rashes, mood changes, or balance issues—should I monitor most closely during this transition?
  4. 4.If I miss a dose, what is the exact protocol I should follow to get back on track safely?
  5. 5.Does this medication interact with any of my other current prescriptions, supplements, or my form of birth control?

References

References (21)
  1. 1

    Treatment Response to Antiseizure Medications in People With Newly Diagnosed Focal Epilepsy.

    Barnard SN, Chen Z, Holmes M, et al.

    JAMA neurology 2025; (82(10)):1022-1030 doi:10.1001/jamaneurol.2025.2949.

    PMID: 40853673
  2. 2

    Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

    Kanner AM, Ashman E, Gloss D, et al.

    Epilepsy currents 2018; (18(4)):260-268 doi:10.5698/1535-7597.18.4.260.

    PMID: 30254527
  3. 3

    Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis.

    Lattanzi S, Zaccara G, Giovannelli F, et al.

    Acta neurologica Scandinavica 2019; (139(1)):33-41 doi:10.1111/ane.13025.

    PMID: 30194755
  4. 4

    Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

    Nevitt SJ, Sudell M, Cividini S, et al.

    The Cochrane database of systematic reviews 2022; (4()):CD011412 doi:10.1002/14651858.CD011412.pub4.

    PMID: 35363878
  5. 5

    The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy.

    Barnard SN, Chen Z, Kanner AM, et al.

    Neurology 2024; (103(7)):e209821 doi:10.1212/WNL.0000000000209821.

    PMID: 39270150
  6. 6

    Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.

    Nevitt SJ, Tudur Smith C, Weston J, Marson AG

    The Cochrane database of systematic reviews 2018; (6()):CD001031 doi:10.1002/14651858.CD001031.pub4.

    PMID: 29952431
  7. 7

    Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

    Yi ZM, - , Wen C, et al.

    Neuropsychiatric disease and treatment 2019; (15()):1-19 doi:10.2147/NDT.S181886.

    PMID: 30587993
  8. 8

    Pharmacological treatment of focal epilepsy in adults: an evidence based approach.

    Mula M

    Expert opinion on pharmacotherapy 2021; (22(3)):317-323 doi:10.1080/14656566.2020.1829594.

    PMID: 32990097
  9. 9

    Psychiatric Outcomes of Antiseizure Medications in Newly Diagnosed Focal Onset Epilepsy: From the Human Epilepsy Project Cohort Study.

    Altalib HH, Nuthalapati P, Zhang Z, et al.

    Neurology. Clinical practice 2026; (16(5)):e200645 doi:10.1212/CPJ.0000000000200645.

    PMID: 42574692
  10. 10

    Which treatment strategy in patients with epilepsy with focal seizures uncontrolled by the first anti-seizure medication?

    Zaccara G, Lattanzi S, Brigo F

    Epilepsy & behavior : E&B 2021; (121(Pt A)):108031 doi:10.1016/j.yebeh.2021.108031.

    PMID: 33992932
  11. 11

    Initiating antiepilepsy treatment: An update of expert consensus in Spain.

    Villanueva V, Sánchez-Álvarez JC, Carreño M, et al.

    Epilepsy & behavior : E&B 2021; (114(Pt A)):107540 doi:10.1016/j.yebeh.2020.107540.

    PMID: 33243687
  12. 12

    Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

    Kanner AM, Ashman E, Gloss D, et al.

    Epilepsy currents 2018; (18(4)):269-278 doi:10.5698/1535-7597.18.4.269.

    PMID: 30254528
  13. 13

    Suicidality at Epilepsy Diagnosis and Future Treatment Resistance in Adults With Focal Epilepsy.

    Barnard SN, French JA, Chen Z, et al.

    JAMA neurology 2026; (83(4)):359-368 doi:10.1001/jamaneurol.2026.0204.

    PMID: 41801192
  14. 14

    Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations.

    Steinhoff BJ, Ben-Menachem E, Klein P, et al.

    Therapeutic advances in neurological disorders 2024; (17()):17562864241256733 doi:10.1177/17562864241256733.

    PMID: 38883228
  15. 15

    Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies.

    Guery D, Rheims S

    Neuropsychiatric disease and treatment 2021; (17()):2229-2242 doi:10.2147/NDT.S256699.

    PMID: 34285484
  16. 16

    Management of Drug-Resistant Epilepsy.

    Nair DR

    Continuum (Minneapolis, Minn.) 2016; (22(1 Epilepsy)):157-72 doi:10.1212/CON.0000000000000297.

    PMID: 26844735
  17. 17

    Seizure control, delivery, and neonatal outcomes in pregnant women with focal epilepsies: a prospective cohort study.

    Melikova S, Mammadbayli A

    Seizure 2025; (134()):117-125 doi:10.1016/j.seizure.2025.11.018.

    PMID: 41352322
  18. 18

    Approach to epilepsy: overview and update of diagnosis and management.

    Kahrom A, Soo C, Arifin N, McGonigal A

    Internal medicine journal 2026; (56(3)):354-363 doi:10.1111/imj.70326.

    PMID: 41527367
  19. 19

    The aging brain and late onset drug-refractory epilepsies.

    Potschka H

    Seizure 2025; (128()):83-89 doi:10.1016/j.seizure.2024.08.021.

    PMID: 39406557
  20. 20

    Early Introduction of Cenobamate in Uncontrolled Focal Epilepsy: Insights from a Structured Controversy.

    Labate A, Liguori C, Tartara E, et al.

    Neurology and therapy 2025; (14(4)):1671-1684 doi:10.1007/s40120-025-00781-3.

    PMID: 40586971
  21. 21

    Drug resistance in epilepsy.

    Perucca E, Perucca P, White HS, Wirrell EC

    The Lancet. Neurology 2023; (22(8)):723-734 doi:10.1016/S1474-4422(23)00151-5.

    PMID: 37352888

This page is for informational purposes only and does not constitute medical advice. Ask your neurologist or epilepsy specialist before changing, missing, or stopping an MTLE-HS medication.